Amalgamated Bank Outlook Therapeutics, Inc. Transaction History

Amalgamated Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$0.22 - $0.66 $200 - $601	-912 Reduced 4.4%	19,795 $8,000
Q2 2023 Aug 11, 2023	BUY	$1.02 - $1.89 $2,160 - $4,003	2,118 Added 11.39%	20,707 $36,000
Q1 2023 May 02, 2023	BUY	$1.0 - $1.35 $934 - $1,260	934 Added 5.29%	18,589 $20,000
Q3 2022 Nov 09, 2022	BUY	$1.02 - $1.26 $309 - $381	303 Added 1.75%	17,655 $22,000
Q2 2022 Aug 15, 2022	BUY	$0.91 - $2.01 $2,595 - $5,732	2,852 Added 19.67%	17,352 $18,000

Q1 2022 Jun 30, 2022	SELL	$1.22 - $2.03 $1,482 - $2,466	-1,215 Reduced 7.73%	14,500 $26,000
Q4 2021 Feb 15, 2022	SELL	$1.27 - $2.23 $463 - $813	-365 Reduced 2.27%	15,715 $21,000
Q3 2021 Oct 29, 2021	SELL	$2.12 - $2.76 $968 - $1,261	-457 Reduced 2.76%	16,080 $35,000
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $29,435 - $45,642	16,537 New	16,537 $41,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.6B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.